Related Experiment Video
Updated: Dec 4, 2025
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11.0K
A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials
Rongji Mu1, Haitao Pan2, Guoying Xu3
1KLATASDS-MOE, School of Statistics, East China Normal University, Shanghai, China.
Statistics in Medicine
|October 23, 2020
Summary
This study introduces a new Bayesian clinical trial design for pediatric cancer immunotherapy. It efficiently evaluates multiple novel treatments simultaneously, improving the evaluation of promising cancer therapies.
Area of Science:
- Oncology
- Clinical Trials
- Immunotherapy
Background:
- Immunotherapy represents a significant advancement in treating pediatric tumors.
- Current clinical trial designs are suboptimal for evaluating numerous novel immunotherapies.
- There is a need for efficient methods to assess multiple new cancer treatments.
Purpose of the Study:
- To propose a novel Bayesian phase I/II platform trial design for pediatric cancer immunotherapy.
- To develop an efficient and seamless method for continuously screening multiple immunotherapeutic treatments.
- To address the limitations of traditional trial designs in evaluating novel cancer therapies.
Main Methods:
- A Bayesian phase I/II platform trial design is proposed.
- The design incorporates a numerical utility function to manage risk-benefit trade-offs.
- Adaptive methods are used to drop ineffective or toxic treatments and graduate promising ones.
- New treatments can be added as others are completed or discontinued.
Main Results:
- The proposed design allows for continuous screening of multiple immunotherapeutic agents.
- It efficiently evaluates novel treatments for pediatric cancers.
- Simulation studies confirm desirable operating characteristics for the trial design.
Conclusions:
- The Bayesian platform trial design offers an optimal approach for evaluating multiple immunotherapies in pediatric cancer.
- This design enhances the efficiency and adaptability of clinical trials for novel cancer treatments.
- It facilitates the rapid progression of promising pediatric cancer immunotherapies.
Related Concept Videos
01:11Clinical Trials: Overview
4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
133
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
133
01:16Clinical Trials
10.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.0K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
105
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
105
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
68
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
68
01:28Preclinical Development: Overview
5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K